Highlights

  • Biotron Limited (ASX:BIT) is progressing BIT-HBV001 through further preclinical development ahead of planned first-in-human studies.
  • FY26 cash and cash equivalents increased to $1.55 million from $931,676 a year earlier, while the annual loss widened to $1.52 million.
  • The Sedarex Acquisition added the SedRx general anaesthetic program, with European regulatory feedback received during 2026.
  • At the time of writing this article, Biotron Limited (ASX:BIT) was trading at AUD 0.002, up 100.00% during today’s trading session.

At the time of writing this article, Biotron Limited (ASX:BIT) was trading at AUD 0.002, up 100.00% during today’s trading session. Biotron is an Australian biotechnology company focused on the funding and management of biotechnology Research and Development projects. Its activities now span antiviral Drug Development and the Sedarex pharmaceutical portfolio. During FY26, the company advanced its hepatitis B virus program, integrated Sedarex and raised additional capital, while September brought a change in executive leadership.

Company Business

Biotron develops small-molecule therapeutic candidates targeting serious viral diseases. Its antiviral portfolio includes BIT-HBV001, the company’s lead compound for hepatitis B virus, or HBV. During FY26, the company also reported antiviral activity against hepatitis Delta virus, or HDV, and filed Patent protection covering BIT-HBV001 and related compounds.

The Business expanded through the acquisition of Sedarex Limited, completed in December 2025. Sedarex holds the SedRx program, which combines alfaxalone with a different solubilising agent for use as a general anaesthetic. Biotron has also been undertaking research into additional neuroscience-related applications for the SedRx platform.

Recent Development

In September 2026, Managing Director and Chief Executive Officer Dr Michelle Miller stepped down for personal reasons after 24 years with Biotron. The board commenced a search for new leadership, while Dr Miller agreed to remain available to support the transition where required.

Operationally, one of the more recent developments has centred on BIT-HBV001. In August 2026, Biotron reported additional studies confirming antiviral activity against HBV and associated HDV infection. Combination studies also assessed BIT-HBV001 alongside an approved HDV treatment. The company said it plans to progress the candidate through formal GLP preclinical studies and manufacture GMP-grade drug product, with the aim of commencing first-in-human studies in the second half of 2027.

Sedarex also reached its first acquisition milestone in July 2026 after receiving European regulatory feedback on the development pathway for SedRx. The feedback indicated that the proposed Hybrid Marketing Authorisation Application pathway was not suitable, meaning further clinical and regulatory work will be required. Biotron said it would focus on planning the pivotal clinical trial or trials required to support a future marketing application.

Financial Performance and Sector Context

For the year ended 30 June 2026, Biotron reported no Revenue from ordinary activities and a net loss of $1.52 million, compared with a loss of $318,572 in FY25. Cash and cash equivalents stood at $1.55 million at year-end, compared with $931,676 a year earlier. Net cash used in Operating Activities was $1.78 million.

During FY26, the company completed a two-tranche Placement raising $1.0 million before costs and an entitlement offer raising approximately $1.52 million before costs. It also received an R&D Tax Incentive rebate of $525,869 relating to work undertaken in FY25.

Biotron operates within the biotechnology and pharmaceutical development sector, where expenditure can occur considerably before commercial revenue is generated. Clinical studies, regulatory engagement, drug Manufacturing and intellectual-property protection therefore remain important factors in the company’s funding requirements and development timetable.

Risks to Consider

Biotron remains exposed to clinical-development risk because its therapeutic programs require further studies before potential commercialisation. Trial outcomes may differ from earlier laboratory or animal results, while regulatory agencies may require additional data or studies.

Funding is another consideration, given the company recorded operating cash outflows during FY26 and continues to progress multiple development programs. Leadership transition, clinical timelines, regulatory requirements and execution of the SedRx development program may also influence future activities.

What to Watch Next

Key developments to monitor include progress towards GLP preclinical studies for BIT-HBV001, manufacture of GMP-grade material and preparations for the targeted first-in-human program in the second half of 2027.

For SedRx, attention will remain on further European regulatory engagement and planning for clinical studies supporting a potential marketing authorisation application. The appointment of a new Managing Director and Chief Executive Officer will also be a corporate development to monitor following the September leadership change.

Future quarterly reports will provide additional information on research expenditure, cash resources and the pace at which the company advances its principal programs.

Key Insights

Biotron entered FY27 with two principal areas of development: its antiviral portfolio led by BIT-HBV001 and the Sedarex pharmaceutical programs led by SedRx. FY26 included the integration of Sedarex, additional HBV and HDV research, Capital raisings and a higher year-end cash balance, while the statutory loss increased.

The next stages centre on regulatory and clinical execution. Progress with BIT-HBV001 towards human studies, further work on SedRx and the company’s funding position are among the main factors to monitor alongside the transition to new executive leadership.